PAM16 and ovarian carcinoma: Investigators found that BT#9, reduced the viability of an ovarian carcinoma carboplatin-resistant cell line (OV9) significantly more than the parental OV90 cell line, suggesting a potential role for Magmas inhibition in overcoming chemotherapeutic resistance [33].